A disintegrin-like metalloproteinase with thrombospondin motif 8 expression analysis in OUMS-27 chondrosarcoma cells before and after insulin administration

ERDEN G. , Akyol S., Comertoglu I., Altuntas A., ÇAKMAK Ö., Ugurcu V., ...More

INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, vol.53, pp.12-16, 2016 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 53
  • Publication Date: 2016
  • Page Numbers: pp.12-16


A disintegrin-like and metalloproteinase with thrombospondin motif 8 (ADAMTS8) is a secreted protease with anti-angiogenic properties. It inhibits vascular endothelial growth factor (VEGF) induced angiogenesis and suppresses fibroblast growth factor 2 (FGF-2) induced vascularization. Angiogenesis and extracellular matrix degradation are the key events in tumor progression, and ADAMTS8 is also known to be a member of the aggrecanases family. In the present study, we investigated the expression levels of ADAMTS8 in chondrosarcoma cells to elucidate the effect of insulin on the tumor cells in terms of ADAMTS production. The OUMS-27 cells were cultured and separately exposed to 10 mu mol/mL insulin up to 11 days in Dulbecco's modified Eagle's medium. After specific time limits (days 1, 3, 7, and 11), the culture was terminated and RNA was isolated using TRIzol reagent and converted to cDNA. The expression levels of ADAMTS8 were evaluated by qRT-PCR. The ADAMTS8 expression in OUMS-27 cells exhibited about 4-fold decrease following insulin treatment on day 11. Statistically significant differences were noted between the control and day 1 (P = 0.008), day 7 (P = 0.047) and day 11 (P = 0.008) groups. The effect of insulin on chondrosarcoma cells in terms of ADAMTS8 expression has not been reported earlier. The decrease in ADAMTS8 expression could be considered as a novel finding that has the potential to explain some pathophysiological mechanisms of tumor cells. Furthermore, the finding could also shed some light on the relationships between matrix degradation and insulin treatment in vitro.